Results 101 to 110 of about 21,646 (232)

Measurement of Active Thrombin Bound to Circulating D‐Dimers as a Sensitive Biomarker for Prothrombotic Conditions

Journal of Clinical Laboratory Analysis, Volume 40, Issue 11, June 2026.
Scheme of preparation of D‐dimers and evaluation of D‐dimer‐bound thrombin activity. Thrombin bound to fibrin participates in ongoing fibrinogen transformation and its inhibition is impeded. Our detection system may aid in identifying patients at risk of recurrent thrombotic events or complications, regardless of the origin of the acute health problem.
Jana Stikarova, Leona Chrastinova, Kristyna Svobodova, Marek Havlicek, Jan Louzil, Eliska Ceznerova, Alzbeta Hlavackova, Ondrej Pastva, Pavla Pecherkova, Ingrid Hrachovinova, Ondrej Kucerka, Roman Kotlin, Petr Soukup, Peter Salaj, Martin Maly, Jiri Suttnar   +15 more
wiley   +1 more source

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice

, 2015
Michael R Preusch,1,2 Nicholas Ieronimakis,1 Errol S Wijelath,3 Sara Cabbage,1 Jerry Ricks,1 Florian Bea,2 Morayma Reyes,1 Joanne van Ryn,4 Michael E Rosenfeld1,5 1Department of Pathology, University of Washington, Seattle, WA, USA; 2Department of ...
Reyes M, Preusch MR, Ieronimakis N, Bea F, van Ryn J, Wijelath ES, Rosenfeld ME, Cabbage S, Ricks J   +8 more
core  

DABIGATRAN AND DENTAL EXTRACTIONS - Case Report

, 2017
For more than 50 years, vitamin K antagonists have been the gold standard in the treatment of cardiovascular and cerebrovascular diseases and in the prevention of their complications.
Atanaska S. Dinkova, Dimitar T. Atanasov, Ludmila G. Vladimirova-Kitova   +2 more
core   +1 more source

Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study

Drugs - Real World Outcomes, 2019
Introduction The new user cohort design is widely used to assess the effects of a new drug, such as dabigatran, but inherently excludes some users due to prior use of the comparator drug, for example warfarin.
Hui-Min Diana Lin, Chao-Lun Lai, Yaa-Hui Dong, Yu-Kang Tu, K. Arnold Chan, Samy Suissa   +5 more
doaj   +1 more source

Dabigatran for Mechanical Valves [PDF]

Hospital Pharmacy, 2014
Effective long-term oral anticoagulant therapy is required in patients who have received mechanical heart valves to reduce the risk of thromboembolism. Patients with mechanical heart valves are at high risk for cardioembolic stroke due to thrombus formation on the valve’s surface.
openaire   +2 more sources

Early Rhythm Versus Rate Control in Older Adults With New‐Onset Atrial Fibrillation: A Propensity Score–Matched Analysis

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
In a large propensity score–matched real‐world cohort of older adults with newly diagnosed atrial fibrillation, early rhythm control was associated with lower thromboembolic and bleeding risk but higher mortality and arrhythmic complications compared with rate control.
Faizan Ahmed, Najam Gohar, Hafsa Arshad Azam Raja, Haris Bin Tahir, Abdullah Masood, Anika Goel, Syed Mubeen Ahmed, Haziq Ahmed, Muhammad Imam, Ameer Haider Cheema, Ramsha Ali, Faseeh Haider, Fawaz Alenezi, Amro Taha   +13 more
wiley   +1 more source

Dabigatran etexilate [PDF]

British Journal of Clinical Pharmacology, 2010
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case‐Crossover Study Using Japanese Administrative Data

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Direct oral anticoagulants (DOACs) offer advantages over warfarin; however, concerns exist regarding their association with acute interstitial lung diseases (ILDs). This study investigated the risk of acute‐onset ILDs associated with DOAC use.
Keisuke Anan, Takahiro Itaya, Yuki Kataoka, Kazuya Ichikado, Kodai Kawamura, Yosuke Yamamoto   +5 more
wiley   +1 more source

Dabigatran (Pradaxa®) [díptic]

, 2018
Anticoagulants orals d’acció directa; Dabigatran; MedicamentsAnticoagulantes orales de acción directa; Dabigatran; MedicamentosDirect-acting oral anticoagulants; Dabigatran; MedicinesPreguntes i respostes sobre l’anticoagulant oral d’acció directa ...

core  

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit–risk ratio

Therapeutic Advances in Neurological Disorders, 2015
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of
Apostolos Safouris, Nikos Triantafyllou, John Parissis, Georgios Tsivgoulis   +3 more
doaj   +1 more source